HUTCHMED

We will be announcing our 2024 interim results on Wednesday, July 31, 2024 at 7am Eastern Daylight Time (EDT) / 12 noon British Summer Time (BST) / 7pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. https://lnkd.in/gQNr5nvR

Since HUTCHMED began its sustainability journey in 2020, we have been integrating sustainability into every aspect of our business decisions and operations, strengthening our governance and endeavoring to align with the latest disclosure requirements, thereby striving to achieve industry best practice.   HUTCHMED scored 49 in the 2023 S&P Global ESG Ratings (90th percentile), significantly higher than the pharmaceutical industry average of 31 points. Mark Lee, Senior Vice President (Corporate Management and Communications) of HUTCHMED, was invited by S&P Global Market Intelligence to share insights on the topic "Unlocking the Potential of Sustainability Data" to more than 300 professionals from various industries around the world at its annual forum held in Hong Kong. Together with other panelists Francis Tong and Olivier Trecco, Mark shared how HUTCHMED has progressed and benefited from taking a more efficient and strategic-focused approach to ESG by upholding the importance of data granularity, including the full spectrum of Scope 3 data, within the Company. Please visit our website to learn more about HUTCHMED’s sustainability: https://lnkd.in/gY4X9aHU

We are happy to share the successful conclusion of our 2024 R&D Day held in Shanghai and through webcast. Over 50 investors attended the event in person and approximately 450 joined online. Our management team shared the latest research advancements and pipeline progress, focusing on three drug candidates poised to address significant global unmet needs: Sovleplenib, our first potential novel medicine for autoimmune diseases; Surufatinib, a potential novel treatment for metastatic pancreatic ductal adenocarcinoma (PDAC); and our IDH1/2 dual inhibitor for acute myeloid leukemia (AML). Listen to the replay: https://lnkd.in/g6MbtnYs

On July 4, 2024, Hong Kong Investor Relations Association (HKIRA) announced the winners of its 10th Investor Relations Awards 2024. HUTCHMED received four awards in the categories of “Best IR by Chairman/CEO”, “Best IR Company”, “Best IR Team” and “Best ESG (E)”. https://lnkd.in/gz67Xp6E Despite the volatile and challenging global economy and market condition, HUTCHMED team remains steadfast in executing our global vision of bringing innovative medicines to patients the world over. Over the last 12 months, we held over 700 meetings with investors through roadshows and conferences throughout China and around the world. There are now 34 sell-side analysts covering HUTCHMED’s stock. Our team will continue to work hard to increase transparency of disclosure, maintain equitable distribution of information, as well as provide prompt and accurate response to queries from investors and other stakeholders.

We are happy to share that the New Drug Application for tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma has been accepted for review and granted Priority Review by the China National Medical Products Administration (NMPA). https://lnkd.in/gFYzVcvJ

We will host in-person presentation and online webinar on Tuesday, July 9, 2024 to share insights into our R&D strategy and vision. Our senior management team will provide updates on certain programs within HUTCHMED’s extensive and innovative pipeline. This will include updates on the Phase III ESLIM‑01 and Phase II/III ESLIM‑02 studies of our Syk inhibitor sovleplenib in ITP and wAIHA respectively; the surufatinib Phase II/III study for metastatic pancreatic ductal adenocarcinoma; and the Phase III RAPHAEL study of our IDH1/2 inhibitor HMPL-306 in acute myeloid leukemia. https://lnkd.in/dVdSwS-F

We are pleased to share that our partner Takeda has received European Commission approval for a new treatment for adults with previously treated metastatic colorectal cancer. It is the first product from our research and discovery engine to be approved in Europe. #ColorectalCancer #mCRC Learn More: https://lnkd.in/gUr7cMxe

We are happy to share that results from ESLIM-01, HUTCHMED’s Phase III trial of sovleplenib in adult patients with primary immune thrombocytopenia (ITP) in China, were published in The Lancet Haematology. Additional details and subgroup results of the study were also presented on June 14 at the European Hematology Association (EHA) 2024 Hybrid Congress as an oral and two poster presentations. https://lnkd.in/gU6YNEtq

We have initiated a Phase I clinical trial of our menin inhibitor HMPL-506 in patients with hematological malignancies in China. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein. https://lnkd.in/g5TvjkxY

We are happy to share that results from the FRUTIGA Phase III trial of fruquintinib in second-line gastric cancer in China have been published in Nature Medicine. Updated efficacy data in key subgroups and data on quality of life (QoL) within this publication were also presented on June 1 at the American Society of Clinical Oncology 2024 Annual Meeting #ASCO24. https://lnkd.in/gdG9Cra3